Alkermes plc. vs Madrigal Pharmaceuticals
Alkermes plc. is the larger business, with $1.48bn of revenue in fiscal 2025 against $958m for Madrigal Pharmaceuticals (1.5 times as much). Madrigal Pharmaceuticals grew faster (432.1% against -5.2%). Alkermes plc. kept more of each dollar of sales as profit: a net margin of 16.4% against -30.1%. Alkermes plc. carries less debt relative to equity (0.0% against 80.6%).
| Latest fiscal year | Alkermes plc.ALKS, 2025 | Madrigal PharmaceuticalsMDGL, 2025 |
|---|---|---|
| Revenue | $1.48bn | $958m |
| Revenue growth | -5.2% | 432.1% |
| Net income | $242m | −$288m |
| Operating margin | 17.2% | -31.3% |
| Net margin | 16.4% | -30.1% |
| Return on equity | 14.7% | -42.5% |
| Free cash flow | $480m | −$190m |
| Cash | $389m | $199m |
| Total debt | $0 | $486m |
| Debt to equity | 0.0% | 80.6% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 2,050 | 915 |
| Market value | $7.84bn | $9.38bn |
| Price vs our value range | Within our value range | — |
| Moat score | 63 (Moderate) | — |
| Insider trades, 12 months | 0 buys, 33 sales | 0 buys, 202 sales |